136 related articles for article (PubMed ID: 11766987)
41. Idarubicin: an anthracycline antineoplastic agent.
Cersosimo RJ
Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
[TBL] [Abstract][Full Text] [Related]
42. Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death.
Gieseler F; Nüssler V; Brieden T; Kunze J; Valsamas S
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):25-8. PubMed ID: 9476145
[TBL] [Abstract][Full Text] [Related]
43. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration.
Demant EJ; Friche E
Biochem Pharmacol; 1998 Jan; 55(1):27-32. PubMed ID: 9413926
[TBL] [Abstract][Full Text] [Related]
44. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.
Michieli M; Michelutti A; Damiani D; Pipan C; Raspadori D; Lauria F; Baccarani M
Leuk Lymphoma; 1993 Feb; 9(3):255-64. PubMed ID: 8097129
[TBL] [Abstract][Full Text] [Related]
45. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
[TBL] [Abstract][Full Text] [Related]
46. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity.
Tokarska-Schlattner M; Wallimann T; Schlattner U
Mol Pharmacol; 2002 Mar; 61(3):516-23. PubMed ID: 11854431
[TBL] [Abstract][Full Text] [Related]
47. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
48. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
49. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
50. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Kwok JC; Richardson DR
Mol Pharmacol; 2003 Apr; 63(4):849-61. PubMed ID: 12644586
[TBL] [Abstract][Full Text] [Related]
51. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.
Pearlman M; Jendiroba D; Pagliaro L; Keyhani A; Liu B; Freireich EJ
Leuk Res; 2003 Jul; 27(7):617-26. PubMed ID: 12681361
[TBL] [Abstract][Full Text] [Related]
52. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes.
Santostasi G; Kutty RK; Krishna G
Toxicol Appl Pharmacol; 1991 Mar; 108(1):140-9. PubMed ID: 2006501
[TBL] [Abstract][Full Text] [Related]
53. The mechanism for anthracycline-induced inhibition of collagen biosynthesis.
Muszyńska A; Wolczyński S; Pałka J
Eur J Pharmacol; 2001 Jan; 411(1-2):17-25. PubMed ID: 11137854
[TBL] [Abstract][Full Text] [Related]
54. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
55. [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].
du Bois A; Lück HJ; Pfisterer J; Meier W; Bauknecht T
Zentralbl Gynakol; 2000; 122(5):255-67. PubMed ID: 10857212
[TBL] [Abstract][Full Text] [Related]
56. Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor.
Heijn M; Roberge S; Jain RK
Cancer Res; 1999 Sep; 59(17):4458-63. PubMed ID: 10485498
[TBL] [Abstract][Full Text] [Related]
57. Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
Zwelling LA; Bales E; Altschuler E; Mayes J
Biochem Pharmacol; 1993 Jan; 45(2):516-20. PubMed ID: 8382067
[TBL] [Abstract][Full Text] [Related]
58. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
59. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
